Advertisement
UK markets close in 3 hours 43 minutes

  • FTSE 100

    7,859.05
    -106.48 (-1.34%)
     

  • FTSE 250

    19,426.78
    -272.11 (-1.38%)
     

  • AIM

    741.66
    -8.62 (-1.15%)
     

  • GBP/EUR

    1.1702
    -0.0009 (-0.08%)
     

  • GBP/USD

    1.2449
    +0.0002 (+0.02%)
     

  • Bitcoin GBP

    50,181.44
    -2,881.89 (-5.43%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CRUDE OIL

    85.10
    -0.31 (-0.36%)
     

  • GOLD FUTURES

    2,389.30
    +6.30 (+0.26%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • DAX

    17,838.01
    -188.57 (-1.05%)
     

  • CAC 40

    7,959.29
    -85.82 (-1.07%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

AstraZeneca to buy oncology-focused Spirogen for up to $440 mln

Reuters - UK Focus

LONDON, Oct (KOSDAQ: 039200.KQ - news) 15 (Reuters) - British drugmaker AstraZeneca (LSE: AZN.L - news) said on Tuesday its MedImmune unit would buy biotech company Spirogen for up to $440 million to bolster its oncology portfolio.

Privately held Spirogen focuses on antibody-drug conjugate technology, which has the potential to directly target cancer tumours while safeguarding healthy cells, AstraZeneca (NYSE: AZN - news) said.

AstraZeneca said it would pay an intial $200 million plus a further $240 million if Spirogen meets development targets. It will also pay $20 million to take an equity investment in ADC Therapeutics, which has a licensing agreement with Spirogen.